Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.
Gresele
Paolo
P
Section of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy. grespa@unipg.it
Marzotti
Stefania
S
Guglielmini
Giuseppe
G
Momi
Stefania
S
Giannini
Silvia
S
Minuz
Pietro
P
Lucidi
Paola
P
Bolli
Geremia B
GB
D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D020030:Nitric Oxide Donors / Q000494:pharmacology / Q000627:therapeutic use*; D015539:Platelet Activation / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D055815:Young Adult
D020030:Nitric Oxide Donors; D010975:Platelet Aggregation Inhibitors; C102148:nitroaspirin; D001241:Aspirin